215 related articles for article (PubMed ID: 32787094)
1. Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.
Gerstenberger BS; Ambler C; Arnold EP; Banker ME; Brown MF; Clark JD; Dermenci A; Dowty ME; Fensome A; Fish S; Hayward MM; Hegen M; Hollingshead BD; Knafels JD; Lin DW; Lin TH; Owen DR; Saiah E; Sharma R; Vajdos FF; Xing L; Yang X; Yang X; Wright SW
J Med Chem; 2020 Nov; 63(22):13561-13577. PubMed ID: 32787094
[TBL] [Abstract][Full Text] [Related]
2. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
[TBL] [Abstract][Full Text] [Related]
3. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.
Wrobleski ST; Moslin R; Lin S; Zhang Y; Spergel S; Kempson J; Tokarski JS; Strnad J; Zupa-Fernandez A; Cheng L; Shuster D; Gillooly K; Yang X; Heimrich E; McIntyre KW; Chaudhry C; Khan J; Ruzanov M; Tredup J; Mulligan D; Xie D; Sun H; Huang C; D'Arienzo C; Aranibar N; Chiney M; Chimalakonda A; Pitts WJ; Lombardo L; Carter PH; Burke JR; Weinstein DS
J Med Chem; 2019 Oct; 62(20):8973-8995. PubMed ID: 31318208
[TBL] [Abstract][Full Text] [Related]
4. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
Norman P
Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
[TBL] [Abstract][Full Text] [Related]
5. Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases.
Mammoliti O; Martina S; Claes P; Coti G; Blanque R; Jagerschmidt C; Shoji K; Borgonovi M; De Vos S; Marsais F; Oste L; Quinton E; López-Ramos M; Amantini D; Brys R; Jimenez JM; Galien R; van der Plas S
J Med Chem; 2024 Jun; 67(11):8545-8568. PubMed ID: 38805213
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of WO2013125543, WO2013146963 and EP2634185: the first Tyk2 inhibitors from Takeda and Sareum.
Norman P
Expert Opin Ther Pat; 2014 Mar; 24(3):361-8. PubMed ID: 24386992
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712.
Breinlinger E; Van Epps S; Friedman M; Argiriadi M; Chien E; Chhor G; Cowart M; Dunstan T; Graff C; Hardee D; Herold JM; Little A; McCarthy R; Parmentier J; Perham M; Qiu W; Schrimpf M; Vargo T; Webster MP; Wu F; Bennett D; Edmunds J
J Med Chem; 2023 Oct; 66(20):14335-14356. PubMed ID: 37823891
[TBL] [Abstract][Full Text] [Related]
8. Design of a peptide inhibitor of tyrosine kinase 2.
Works MG; Song B; Kibler P; Tanga MJ; Galande AK; D'Andrea A
Protein Pept Lett; 2014 May; 21(5):419-25. PubMed ID: 24304386
[TBL] [Abstract][Full Text] [Related]
9. TYK2: an emerging therapeutic target in rheumatic disease.
Morand E; Merola JF; Tanaka Y; Gladman D; Fleischmann R
Nat Rev Rheumatol; 2024 Apr; 20(4):232-240. PubMed ID: 38467779
[TBL] [Abstract][Full Text] [Related]
10. Discovery of selective TYK2 inhibitors: Design, synthesis, in vitro and in silico studies of promising hits with triazolopyrimidinone scaffold.
Istanbullu H; Coban G; Turunc E; Disel C; Debelec Butuner B
Bioorg Chem; 2024 Jul; 148():107430. PubMed ID: 38728909
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of tyrosine kinase 2 in autoimmunity.
Liang Y; Zhu Y; Xia Y; Peng H; Yang XK; Liu YY; Xu WD; Pan HF; Ye DQ
Expert Opin Ther Targets; 2014 May; 18(5):571-80. PubMed ID: 24654603
[TBL] [Abstract][Full Text] [Related]
12. Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences.
Gerstenberger BS; Banker ME; Clark JD; Dowty ME; Fensome A; Gifford R; Griffor MC; Hegen M; Hollingshead BD; Knafels JD; Lin TH; Smith JF; Vajdos FF
Sci Rep; 2020 Jun; 10(1):8974. PubMed ID: 32488071
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases.
Muromoto R; Shimoda K; Oritani K; Matsuda T
Biol Pharm Bull; 2021; 44(11):1585-1592. PubMed ID: 34719635
[TBL] [Abstract][Full Text] [Related]
14. Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1.
Fensome A; Ambler CM; Arnold E; Banker ME; Clark JD; Dowty ME; Efremov IV; Flick A; Gerstenberger BS; Gifford RS; Gopalsamy A; Hegen M; Jussif J; Limburg DC; Lin TH; Pierce BS; Sharma R; Trujillo JI; Vajdos FF; Vincent F; Wan ZK; Xing L; Yang X; Yang X
Bioorg Med Chem; 2020 May; 28(10):115481. PubMed ID: 32253095
[TBL] [Abstract][Full Text] [Related]
15. Lead identification of novel and selective TYK2 inhibitors.
Liang J; Tsui V; Van Abbema A; Bao L; Barrett K; Beresini M; Berezhkovskiy L; Blair WS; Chang C; Driscoll J; Eigenbrot C; Ghilardi N; Gibbons P; Halladay J; Johnson A; Kohli PB; Lai Y; Liimatta M; Mantik P; Menghrajani K; Murray J; Sambrone A; Xiao Y; Shia S; Shin Y; Smith J; Sohn S; Stanley M; Ultsch M; Zhang B; Wu LC; Magnuson S
Eur J Med Chem; 2013 Sep; 67():175-87. PubMed ID: 23867602
[TBL] [Abstract][Full Text] [Related]
16. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
He X; Chen X; Zhang H; Xie T; Ye XY
Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
[TBL] [Abstract][Full Text] [Related]
17. Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
Malerich JP; Lam JS; Hart B; Fine RM; Klebansky B; Tanga MJ; D'Andrea A
Bioorg Med Chem Lett; 2010 Dec; 20(24):7454-7. PubMed ID: 21106455
[TBL] [Abstract][Full Text] [Related]
18. Potent and selective TYK2-JH1 inhibitors highly efficacious in rodent model of psoriasis.
Leit S; Greenwood JR; Mondal S; Carriero S; Dahlgren M; Harriman GC; Kennedy-Smith JJ; Kapeller R; Lawson JP; Romero DL; Toms AV; Shelley M; Wester RT; Westlin W; McElwee JJ; Miao W; Edmondson SD; Masse CE
Bioorg Med Chem Lett; 2022 Oct; 73():128891. PubMed ID: 35842205
[TBL] [Abstract][Full Text] [Related]
19. Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model.
Liang J; Van Abbema A; Balazs M; Barrett K; Berezhkovsky L; Blair WS; Chang C; Delarosa D; DeVoss J; Driscoll J; Eigenbrot C; Goodacre S; Ghilardi N; MacLeod C; Johnson A; Bir Kohli P; Lai Y; Lin Z; Mantik P; Menghrajani K; Nguyen H; Peng I; Sambrone A; Shia S; Smith J; Sohn S; Tsui V; Ultsch M; Williams K; Wu LC; Yang W; Zhang B; Magnuson S
Bioorg Med Chem Lett; 2017 Sep; 27(18):4370-4376. PubMed ID: 28830649
[TBL] [Abstract][Full Text] [Related]
20. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841).
Fensome A; Ambler CM; Arnold E; Banker ME; Brown MF; Chrencik J; Clark JD; Dowty ME; Efremov IV; Flick A; Gerstenberger BS; Gopalsamy A; Hayward MM; Hegen M; Hollingshead BD; Jussif J; Knafels JD; Limburg DC; Lin D; Lin TH; Pierce BS; Saiah E; Sharma R; Symanowicz PT; Telliez JB; Trujillo JI; Vajdos FF; Vincent F; Wan ZK; Xing L; Yang X; Yang X; Zhang L
J Med Chem; 2018 Oct; 61(19):8597-8612. PubMed ID: 30113844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
